You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

CLINICAL TRIALS PROFILE FOR THIOPENTAL SODIUM


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Thiopental Sodium

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00142493 ↗ Effect of Affective Content on Drug Induced Amnesia of Episodic Memory Completed Memorial Sloan Kettering Cancer Center Phase 1 2004-09-01 The purpose of this research is to understand how some of the drugs commonly used in anesthesia impair memory. We are particularly interested in whether the emotion associated with a memory influences how well these drugs are able to block memory. We are studying four commonly used drugs-propofol, thiopental, midazolam, and dexmedetomidine, all of which may have slightly differing effects. We will also study an inactive substance, called a placebo, that should have no effect. The results of this study will provide information that will be useful in understanding how memory works, how these drugs affect memory, and possibly why some people don't have their memory blocked as easily as others.
NCT00521612 ↗ Sevoflurane vs. Isoflurane for Low-Flow General Anaesthesia for Abdominal Surgery Completed General Hospital Dubrovnik N/A 2007-09-01 Two groups of patients are going to have abdominal surgery with low-flow general anaesthesia. Group A (sevoflurane group, experimental group) will use volatile anaesthetic sevoflurane. Group B (isoflurane group, control group) will use volatile anaesthetic isoflurane. It will be observed differences between volatile anaesthetic sevoflurane and volatile anaesthetic isoflurane for providing low-flow general anaesthesia for abdominal surgery. Duration of this randomised controled trial will be approximately 2 months. Estimated sample size will be 82 persons (41 in sevoflurane group and 41 in isoflurane group).
NCT00978757 ↗ The Effect of Ketamine on Interleukin-6 Synthesis in Hepatic Resections Requiring Temporary Porto-arterial Occlusion Completed Hospital Italiano de Buenos Aires Phase 4 2001-06-01 The purpose of this study is to determine whether ketamine is effective to inhibit interleukin 6 synthesis in hepatic resections requiring temporary porto-arterial occlusion.
NCT01005433 ↗ Dexmedetomidine for Cesarean Delivery Completed King Faisal University Phase 1 2009-12-01 Regional anesthesia has become the anesthetic of choice for cesarean section in most countries; however, some women still prefer general anesthesia techniques. There are many trials for the pharmacological modifications of the sympathetic response to surgery, including opioids, tenoxicam, ketorolac, lidocaine and paracetamol. However, opioid administration to the mother before delivery has adverse neonatal effects. This research is a novel trial on the use of dexmedetomidine for suppression of the hemodynamic and hormonal responses of cesarean delivery.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Thiopental Sodium

Condition Name

Condition Name for Thiopental Sodium
Intervention Trials
Supraventricular Tachycardia 1
Hepatectomy 1
Vomiting 1
Maternal Hypotension 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Thiopental Sodium
Intervention Trials
Emergence Delirium 2
Cardiovascular Diseases 1
Delirium 1
Vomiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Thiopental Sodium

Trials by Country

Trials by Country for Thiopental Sodium
Location Trials
Egypt 3
Argentina 1
Albania 1
Croatia 1
Thailand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Thiopental Sodium
Location Trials
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Thiopental Sodium

Clinical Trial Phase

Clinical Trial Phase for Thiopental Sodium
Clinical Trial Phase Trials
Phase 4 4
Phase 1/Phase 2 1
Phase 1 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Thiopental Sodium
Clinical Trial Phase Trials
Completed 13
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Thiopental Sodium

Sponsor Name

Sponsor Name for Thiopental Sodium
Sponsor Trials
Ain Shams University 3
King Faisal University 1
Mahidol University 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Thiopental Sodium
Sponsor Trials
Other 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Thiopental Sodium: Clinical Trials, Market Analysis, and Projections

Introduction to Thiopental Sodium

Thiopental sodium, commonly known by its brand name Pentothal, is a barbiturate used primarily for inducing anesthesia in patients undergoing surgical procedures. It has been a crucial component in medical practice for decades, although its usage has evolved over time.

Clinical Use and Efficacy

Anesthesia Induction

Thiopental sodium is used to help patients relax before receiving general anesthesia with an inhaled medication. The typical induction dose for an average adult is 50 to 75 mg, administered in fractional doses to avoid respiratory depression and other adverse effects[4].

Special Patient Groups

Despite the introduction of newer anesthetics like propofol, thiopental sodium remains a first-line anesthetic for certain patient groups, including geriatric, neurologic, cardiovascular, and obstetric patients, due to its favorable side effect profile in these populations[1].

Clinical Trials and Studies

Brain Resuscitation After Cardiac Arrest

A randomized clinical study investigated the use of thiopental for brain resuscitation after cardiac arrest. The study found no statistically significant difference in outcomes between patients receiving thiopental and those receiving standard therapy, concluding that thiopental does not support brain resuscitation in this context[3].

General Anesthesia

Clinical trials and practical use have established thiopental sodium as an effective agent for inducing general anesthesia. However, its use must be carefully managed to avoid deep anesthesia or respiratory depression, particularly in sensitive patients[4].

Market Analysis

Market Size and Growth

The global thiopental sodium market has experienced significant growth in recent years and is projected to continue this trend from 2023 to 2031. The market is anticipated to reach substantial values, driven by its various applications in anesthesia, medical use for coma, euthanasia, and other medical purposes[2].

Segmentation

The market is segmented by type (99% purity and other), application (anesthesia, medical use for coma, euthanasia, lethal injection, and other), and geography (North America, Europe, Asia-Pacific, South America, and Middle East & Africa). This segmentation helps in understanding the diverse demand and supply dynamics across different regions and applications[2].

Key Players

Prominent companies in the thiopental sodium market include Chemische Fabrik Berg, Taj Pharmaceuticals, and Salvavidas Pharmaceutical. These companies play a crucial role in the production and distribution of thiopental sodium, influencing market trends and growth[2].

Market Projections

Forecast Period

From 2023 to 2031, the thiopental sodium market is expected to exhibit robust growth rates. This projection is based on a comprehensive analysis of market dynamics, including drivers, restraints, opportunities, and challenges. The market is anticipated to expand significantly, driven by increasing demand in various medical applications[2].

Drivers and Restraints

Key drivers of the market include the ongoing need for effective anesthetic agents, especially in specialized patient groups. However, restraints such as the availability of alternative anesthetics and regulatory challenges can impact market growth. The use of thiopental sodium in capital punishment has also led to distribution issues in the past, highlighting the need for robust manufacturing and distribution systems[1][2].

Geographical Insights

The market is geographically diverse, with North America, Europe, and Asia-Pacific being significant regions. Each region has its own set of market dynamics, influenced by local healthcare policies, economic conditions, and consumer behavior. Understanding these regional differences is crucial for market strategy and investment decisions[2].

Challenges and Future Directions

Drug Shortages

The removal of thiopental sodium from the market in the United States due to manufacturing cessation by Hospira highlighted the critical issue of drug shortages. The American Society of Anesthesiologists (ASA) has been actively working to address these shortages, emphasizing the need for redundancies in manufacturing and distribution systems to ensure patient safety[1].

Regulatory and Ethical Considerations

The use of thiopental sodium in capital punishment has raised ethical concerns and led to regulatory challenges. However, it is essential to distinguish between its legitimate medical use and other applications to ensure that patients have access to this critical drug when needed[1].

Key Takeaways

  • Clinical Efficacy: Thiopental sodium remains an effective anesthetic agent, particularly for specialized patient groups.
  • Market Growth: The global thiopental sodium market is projected to grow significantly from 2023 to 2031.
  • Segmentation: The market is segmented by type, application, and geography, each with unique dynamics.
  • Challenges: Drug shortages and regulatory issues are key challenges that need to be addressed.
  • Future Directions: Ensuring robust manufacturing and distribution systems and distinguishing between medical and non-medical uses are crucial for the future of thiopental sodium.

FAQs

What is the primary use of thiopental sodium in medical practice?

Thiopental sodium is primarily used to induce anesthesia in patients undergoing surgical procedures.

Why has the use of thiopental sodium decreased in recent years?

The use of thiopental sodium has decreased due to the introduction of newer anesthetic agents like propofol, although it remains a first-line anesthetic for certain patient groups.

What are the key drivers of the thiopental sodium market?

Key drivers include the ongoing need for effective anesthetic agents, especially in specialized patient groups, and the increasing demand in various medical applications.

What are the main challenges facing the thiopental sodium market?

Challenges include drug shortages, regulatory issues, and the ethical concerns surrounding its use in capital punishment.

Which regions are significant in the global thiopental sodium market?

North America, Europe, and Asia-Pacific are significant regions in the global thiopental sodium market, each with its own market dynamics.

Sources

  1. ASA Statement on Sodium Thiopental's Removal From the Market - American Society of Anesthesiologists.
  2. Global Thiopental Sodium Market Size, Scope And Forecast Report - Market Research Intellect.
  3. Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest - PubMed.
  4. Pentothal (Thiopental Sodium): Side Effects, Uses, Dosage - RxList.
  5. Thiopental Sodium - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 - Market Research ReportsĀ® Inc.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.